Palatin Technologies Inc(PTN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.08 | Insider Own | 5.58% | Shs Outstand | 1.8M | Perf Week | -8.11% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 2.6% | Insider Trans | - | Shs Float | 1.7M | Perf Month | -44.08% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.42 | Inst Own | 49.63% | Short Float | 19.78% | Perf Quarter | -34.7% |
| Income | -0.01B | P/S | 0.69 | EPS this Y | 26.24% | Inst Trans | 0.39% | Short Ratio | 4.92 | Perf Half Y | -74.84% |
| Sales | 0.01B | P/B | 1.36 | EPS next 5Y | 3.08% | ROA | -142.11% | Short Interest | 0.33M | Perf YTD | -66.84% |
| Book/sh | 3.76 | P/C | 1.21 | EPS past 3/5Y | 70.06% 55.89% | ROE | -877.53% | 52W High | -83.55% ($31.00) | Perf Year | -14.29% |
| Cash/sh | 4.2 | P/FCF | - | Sales past 3/5Y | 39.53% - | ROIC | -124.08% | 52W Low | 11.35% ($4.58) | Perf 3Y | -94.8% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 101.28% | Gross Margin | - | Volatility(W/M) | 12.92% 11.76% | Perf 5Y | -99.01% |
| Dividend TTM | - | EV/Sales | 0.14 | Sales Y/Y TTM | 3581.22% | Oper. Margin | -65.74% | ATR (14) | 0.85 | Perf 10Y | -99.19% |
| Dividend Ex-Date | - | Quick Ratio | 4.61 | EPS Q/Q | 53.65% | Profit Margin | -63.54% | RSI (14) | 24.97 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.61 | Sales Q/Q | - | SMA20 | -28.9% ($7.17) | Beta | 0.69 | Target Price | $53.5 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/9/28 | SMA50 | -45.49% ($9.36) | Rel Volume | 0.63 | Prev Close | $4.77 |
| Employees | 25 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 7.5% -79.97% | SMA200 | -63.99% ($14.16) | Avg Volume(3M) | 0.07M | Price | $5.1 |
| IPO | 1993/10/28 | Option/Short | No/Yes | Trades | 515 | Volume | 42,461 | Change | 6.92% |
💊 A melanocortin-focused biotech that developed Vyleesi®, an FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in women. The company is currently advancing a Phase 3 clinical trial of bremelanotide combination therapy for men with erectile dysfunction who are unresponsive to PDE5 inhibitors (such as Viagra-class drugs).
Over the past 1 year, on the lower side
84% below its 1-year high.
Traded less than usual. That is 63% of its average volume.
PTN has a sound balance sheet but weak earning power
Of every $100 in sales, $65.74 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +26.2% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $69. Peers typically go for $1,089. Compared with its own 2-year average, it is 99% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 49.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #511 of 594 in the industry
Based on market cap of $9M.
ACTU#508 Actuate Therapeutics Inc $9M PER - 
MBRX#509 Moleculin Biotech Inc $9M PER - 
TPST#510 Tempest Therapeutics Inc $9M PER - PTN#511 Palatin Technologies Inc $9M PER - 
ENSC#512 Ensysce Biosciences Inc $9M PER - 
FAQ
What kind of company is PTN?
PTN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PTN?
The market cap of PTN is approximately $9M, ranking 5,465 within its sector.
What is the 52-week high and low for PTN?
PTN has recorded a 52-week high of $31.00 and a low of $4.58.
